Rankings
▼
Calendar
ICCC
ImmuCell Corporation
$60M
Q1 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$7M
+110.6% YoY
Gross Profit
$2M
31.6% margin
Operating Income
-$300,050
-4.1% margin
Net Income
-$437,868
-6.0% margin
EPS (Diluted)
$-0.06
QoQ Revenue Growth
+42.4%
Cash Flow
Operating Cash Flow
$418,505
Free Cash Flow
$348,149
Stock-Based Comp.
$81,110
Balance Sheet
Total Assets
$43M
Total Liabilities
$18M
Stockholders' Equity
$25M
Cash & Equivalents
$960,347
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$7M
$3M
+110.6%
Gross Profit
$2M
$300,775
+663.1%
Operating Income
-$300,050
-$2M
+86.7%
Net Income
-$437,868
-$2M
+81.1%
Geographic Segments
UNITED STATES
$6M
100%
← FY 2024
All Quarters
Q2 2024 →
ICCC Q1 2024 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena